



Anora™
Miscarriage test (POC)

Anora™ Miscarriage Test (POC)

Get actionable answers quickly
with the most comprehensive
products of conception (POC) test

A single test provides insights and informs next steps for your patients

When a miscarriage occurs, you and your patients want reliable answers—fast.



Anora is a genetic test that can determine why a miscarriage occurred, by testing for chromosomal abnormalities on tissue from a pregnancy loss (otherwise known as products of conception, or POC). Anora results are typically returned within one week—quickly providing insights to inform next steps.

Many patients wonder why a miscarriage occurred and will often question whether or not their own choices were the cause. Anora can help answer why a miscarriage happened and reduce emotional burden to enable them to confidently plan future care.

In a recent study, 95% of patients who had chromosomal analysis after their miscarriage were glad they did; 2/3 who did not, wished they had.¹

Answers to questions your patients don't know to ask

Quick facts for your patients

Up to 25% of recognized pregnancies end in a miscarriage²

Anora allows you to determine which patients need a medical workup. It can also provide input to help identify which patients are clinically ready to try to conceive again.

50 to 70% of miscarriages are caused by spontaneous chromosomal abnormalities³


Studies have shown that the likelihood of a successful pregnancy almost doubles if the initial loss can be explained by a chromosomal abnormality. Anora can confirm the genetic cause of a pregnancy loss.^{4,5}

There is a 28% risk of another miscarriage after two miscarriages⁶


No one wants to have another miscarriage. Anora can provide insights on the potential cause of recurrent pregnancy loss from both fresh and paraffin-preserved tissue.

Identification of Miscarriage Etiology

Without chromosomal analysis



With chromosomal analysis



⁷Results are from women with recurrent pregnancy loss who are 35 years or older.

Have confidence in next steps with the most comprehensive POC test

For more than a decade, Anora has been used to determine whether a chromosomal abnormality was the likely cause of a miscarriage. Natera's single nucleotide polymorphism (SNP) microarray technology detects aneuploidies, uniparental disomy (UPD), all deletions and duplications 5 Mb or larger, and select deletions and duplications down to 1 Mb.

Natera's 10-year Anora study is the largest POC study to date, with over 63,000 POC samples analyzed. It demonstrates how Anora overcomes the limitations of standard karyotyping:⁸

	KARYOTYPING (CYTOGENETIC)	ANORA (SNP MICROARRAY ANALYSIS)
Rules out maternal cell contamination (MCC) from a normal female result	✗ ^{8,9,10}	✓ ^{8,9,10}
Detects partial and complete molar pregnancies	✗ ¹¹	✓ ¹¹
Test failure rate	10-40% ¹²	<0.5% ⁸
Turnaround time	2-5 weeks	Within 1 week

Anora is the only array-based POC test that can:

- Rule out MCC in a single test
- Determine parental origin of a chromosomal abnormality



Only Natera detects MCC in every sample tested

The ability to distinguish results as maternal vs. fetal can eliminate additional costly medical workup and incorrect conclusions. If MCC is detected, a second dissection will be performed automatically.

Only Anora detects paternal origin of triploidy and full paternal UPD, associated with partial and complete molar pregnancies

Molar pregnancies carry serious risks due to the potential for Gestational Trophoblastic Disease (GTD). All women with molar pregnancies require monitoring of their blood hCG levels and follow-up maternal care post-pregnancy. If found, GTD requires treatment with chemotherapy.¹³

	PARTIAL MOLAR PREGNANCY (PATERAL ORIGIN OF TRIPLOIDY)	COMPLETE MOLAR PREGNANCY (FULL PATERAL UPD)
Percentage of cases missed by standard testing (ultrasound and/or histopathology)	71% ¹¹	30% ¹¹
Percentage of cases at risk for GTD	5% ¹¹	20% ¹¹

45% of triploidy cases are of paternal origin and need follow-up for GTD.¹¹ Natera's Parental Support™ bioinformatics technology enables Anora to identify these cases by determining parental origin of chromosomal abnormalities.



Choose Anora Elevate the standard of care



Get definitive results >99% of the time. Compared to standard methods like karyotyping, which can return no result due to failed cell culture growth. Anora yields a much higher result rate. It also can detect smaller deletions and duplications compared to traditional karyotyping.^{8,9}



Get comprehensive information in a single test. Anora is the most comprehensive of all POC tests available, ruling out MCC in a single test, and detecting aneuploidies, UPD, partial and complete molar pregnancies and more. With Natera's exclusive Parental Support™ technology, Anora uniquely identifies parental origin of chromosomal abnormalities.⁹



Get insights sooner. With a faster turnaround time compared to traditional karyotyping,⁹ there's no need to delay medical workup—reducing stress and anxiety for your patients, and allowing them to take their next steps faster.¹⁴

Affordability for your patients:

Natera is committed to providing affordable testing to all who can benefit. The majority of insurance providers cover miscarriage testing if patients have experienced 2 or more miscarriages. Additionally, almost all insurers cover genetic testing for pregnancy losses that are >20 weeks gestation.

Most patients receiving reproductive care meet their deductible and the out-of-pocket cost for their test is **less than \$349**.



Frequently Asked Questions

Can I test on prior losses?

Yes, Anora can be performed on paraffin-preserved tissue samples from a prior miscarriage. This can be particularly beneficial to help counsel patients with recurrent pregnancy loss.

Am I able to order Anora for patients who miscarry at home?

Yes, at-home collection instructions are available to patients and Natera can send kits directly to patients' homes.

Learn more at natera.com/anora-at-home

What samples are required for Anora testing?

A pea-sized amount of fetal tissue is required, which is less than required for cytogenetic karyotyping. Instructions for optimal sample collection are available at natera.com/poc-tissue-sorting

A maternal blood or cheek swab sample is also needed to rule out MCC.



NateraCore

— simple, tailored resources to support you and your patients every step of the way

Education

Patient-friendly materials and information sessions, covering basic genetics to specific tests

Access

Programs and price transparency – rooted in our commitment to provide affordable testing for all who can benefit

Ordering

Flexible options based around your needs, including intuitive remote ordering and comprehensive EMR solutions

Results

Clear, actionable reports, coupled with time-saving tools and expert guidance

Next steps

Value-add services that go beyond the test to address what's next

A selection of our NateraCore offerings

Pre- and post-test genetic information sessions

– access to board-certified genetic counselors, available to all providers and patients



Price Transparency Program (PTP)

– personalized cost estimates and an affordable self-pay cash option



For questions or to order Anora, contact your Natera local representative or call 1.844.778.4700.

Learn more about Anora at:
natera.com/anora

References:

1. Lathi et al. *Fertil Steril.* 2011;96(3):S91.
2. Practice Committee of the American Society for Reproductive Medicine. *Fertil Steril.* 2012;98(5):1103-11.
3. Hyde and Schust. *Cold Spring Harb Perspect Med.* 2015;5(3):a023119.
4. Ogasawara et al. *Fertil Steril.* 2000;73(2):300-4.
5. Carp et al. *Fertil Steril.* 2001;75(4):678-82.
6. <https://www.mayoclinic.org/healthy-lifestyle/getting-pregnant/in-depth/pregnancy--after-miscarriage/art-20044134>. Accessed August 2021.
7. Marquard et al. *Fertil Steril.* 2010;94(4):1473-7.
8. Maisenbacher, et al. *Fertil Steril.* 2020;1114(3):E47.
9. Shah et al. *Fertil Steril.* 2019;107(4):1028-33.
10. Levy et al. *Obstet Gynecol.* 2014;123(2 pt1):202-9.
11. Maisenbacher et al. *Fertil Steril.* 2019;112(4):700-6.
12. Lomax et al. *Am J Hum Genet.* 2000;66:1516-21.
13. <http://www.americanpregnancy.org/pregnancycomplications/molarpregnancy.html>. Accessed August 2021.
14. Papas and Kutteh. *Curr Opin Obstet Gynecol.* 2020;32:371-9.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

Anora has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
© 2021 Natera, Inc. All Rights Reserved. NAT-9000063

